Printer Friendly

Endologix Appoints Vice President of Quality.

IRVINE, Calif. -- Endologix, Inc. (Nasdaq: ELGX), developer of the Powerlink([R]) System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), announces the expansion of its management team with the appointment of Gary I. Sorsher as Vice President, Quality, effective October 1, 2008. Mr. Sorsher brings 20 years of quality assurance experience, including the past 15 years in medical devices with Bard Peripheral Vascular and Cordis, a Johnson & Johnson Company.

"We are adding another experienced industry veteran to our management team to provide additional depth and leadership to support our growth," said John McDermott, Endologix President and Chief Executive Officer. "Gary has developed and implemented effective quality and risk management systems both domestically and internationally, and has a proven track record for successfully introducing new products in the vascular market. He has a strong technical background and a hands-on leadership style that will be an exceptional fit with Endologix."

Most recently, Mr. Sorsher served for two years as Director of Quality Engineering at Bard Peripheral Vascular, where he oversaw quality assurance operations for Bard Peripheral Vascular and Bard Biopsy Systems. Prior to that, he spent 13 years at Cordis, a Johnson & Johnson Company holding several positions with increasing responsibility during his tenure. As Director of Quality Assurance - New Product Development, he provided technical and strategic guidance to global engineering teams to facilitate timely and cost-effective deployment of robust designs and processes. He also served as the senior quality assurance representative for Cordis' Global Commercialization Team responsible for drug eluting stents, stent delivery systems and angioplasty products. Mr. Sorsher received a Master of Science and Bachelor of Science in electrical engineering from Byelorussian Polytechnic Institute, USSR.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endovascular stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 22, 2008
Previous Article:Phyworks: Equalizer Clears Way to 8.5G Upgrades.
Next Article:JNetDirect Teams with Dataupia to Deliver a Complete BI and Data Warehousing Solution.

Related Articles
CryoLife signs agreement with Endologix to develop and market BioFoam, files shelf registration statement.
Endologix Announces Limited Voluntary Recall of Powerlink System Delivery Catheter; Recall Does Not Involve Devices Implanted in Patients; Scheduled...
Endologix Approved to Manufacture Powerlink System at New Facility; Company's Voluntary Limited Recall Completed; Corrective Action Implemented.
Endologix Announces Limited Voluntary Recall of Visiflex 155 mm Delivery Catheters.
Endologix Announces Successful Powerlink Deployments with Advanced Visiflex Integrated System.
Cook Wins Injunction Against Competitor and Former Sales Representatives Over Violations of Employee Non-Compete Agreements.
Endologix Names John McDermott President and CEO.
Endologix Appoints Vice President of Sales.
John McDermott named president, CEO of Endologix.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters